Navigation Links
SemBioSys initiates toxicology study for safflower-produced insulin
Date:3/26/2008

Initiation of study puts company on track for Phase I/II trial

TSX symbol: SBS

CALGARY, March 26 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX: SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced that it has initiated a toxicology study in animals to demonstrate the safety and comparability of its safflower-produced insulin to pharmaceutical grade human insulin. This study is a final key step in the Company's preparations to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in the third quarter in order to initiate a Phase I/II human clinical trial this year. The 28-day repeat dose study in monkeys and rats is the only toxicology study required before submission of the IND application to the FDA. The study is also a required component for the abbreviated 505(b)(2) application process that SemBioSys is eligible to follow, based on the well-characterized nature of insulin. The study aims to establish that the toxicology profile of insulin produced from SemBioSys' plant system is appropriate to begin human trials.

"Insulin is currently one of the largest volume recombinant biopharmaceutical products on the market and demand is projected to increase dramatically in the coming years. The scalability of our safflower-produced insulin has the potential to provide a cost-effective source of insulin to meet this growing demand," said Andrew Baum, President and CEO of SemBioSys. "In order to start the toxicology study we had to demonstrate that our safflower-produced insulin is chemically, physically and structurally equivalent to human insulin using a broad array of assays. The toxicology study is an important milestone for our insulin program and demonstrates that we are on track to begin human clinical trials in the second half of 2008."

SemBioSys has already established
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. SemBioSys announces 2007 financial and operational results
2. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
3. SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office
4. SemBioSys to present at the 10th Annual BIO CEO & Investor Conference
5. SemBioSys signs option agreement for safflower-produced food ingredient
6. SemBioSys announces 2007 third quarter results
7. SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting
8. SemBioSys updates Apo AI development program
9. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
10. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
11. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)... Helix BioPharma Corp. (T...ed that John Docherty, president and chief operati... 6th annual Investor Summit on November 10, 2009 a...Mr. Docherty will provide an overview of the Compa...and Topical Interferon Alpha-2b. The slide show p...
(Date:11/6/2009)...ember 6 EUCODIS Bioscience, a comp...rketing enzymes for the,chemical industry announce...ent with Bio Sidus, the leading biopharmaceutical ... gives EUCODIS Bioscience exclusive access - for t...roprietary collection of,psychrophilic bacteria st...
(Date:11/6/2009)...ov. 6 Calbiotech, Inc. announced t...ovative Research (SBIR) Phase I contract by the U....er terms of the agreement, Calbiotech will develop...s of Dengue virus. ,, Dengue virus is a mosq...t to military forces deployed to tropical areas of...
(Date:11/6/2009)... Intarcia Therapeutics, Inc. delive...® continuous delivery of exenatide) program f...nnual Diabetes Technology Meeting in San Francisco.../prnh/20050301/SFTU126LOGO ) ,, Continuous Su...rs Plasma Glucose, HbA1c and Reduces Weight in a 2...
Breaking Biology Technology:Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 2Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 3EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus 2Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5
....S. Patent and Trade Office issued U.S. Patent No....lymerase and Uses Thereof to the Wisconsin Alumni...y of the University of Wisconsin-Madison. ConjuGo...lectual property invented by its co-founder Richar...research group, which included ConjuGon scientist ...
...le System was chosen by Popular Science magazine ..., ,To be among the 100 selected by Popular Science...chnology must represent a significant step forward...ble System features In-Cell Charge Control (I-C3)t... the battery, instead of the charger. This breakt...
...built the supply chain industries first fully func...adio frequency identification (RFID) laboratory d...vironment. The RFID Lab is enabling RedPrairie cus...t and readability as they prepare for RFID complia...scenarios, the RFID Lab is helping companies deter...
Other Biology Technology:RedPrairie Builds RFID Lab - Enables Real-World Testing 2
(Date:11/9/2009)... LAS VEGAS, Nov. 9 CBS Vision, the...gency OMD, an Omnicom Media Group company, today a...w OMD,s clients access to the CBS Television City ... Las Vegas. ,, The new venture, which marries ...nty,s leading agencies, will be called Communicati...
(Date:11/9/2009)..., N.Y. Oncologists have had their hands tied beca...ions that disable a protein called p53. As a criti...cancer-fighting operations within cells. When cell...not be treated. , These tumors might be tough, ...rom Cold Spring Harbor Laboratory (CSHL). The chin...
(Date:11/9/2009)...f butterfly wings has inspired a 3.2m, three-year ...on in the fields of security, energy and the envir... technology company QinetiQ have just signed a col...sed on groundbreaking physical sciences research. ...s from the University of Exeter and QinetiQ will w...
Breaking Biology News(10 mins):CBS and OMD Partner to Provide the Agency With Access to the Network's Television City Research Facility in Las Vegas 2CBS and OMD Partner to Provide the Agency With Access to the Network's Television City Research Facility in Las Vegas 3CBS and OMD Partner to Provide the Agency With Access to the Network's Television City Research Facility in Las Vegas 4CSHL study shows that some malignant tumors can be shut down after all 2CSHL study shows that some malignant tumors can be shut down after all 3£3.2m ($5.4 million) research project to capture brilliance of butterfly wings 2Finances Trigger American Reluctance to Spend More on Healthier Foods 49018 1Finances Trigger American Reluctance to Spend More on Healthier Foods 49018 2Despite Generic Erosion of Key Brands the Hospital Acquired Gram Negative Infections Drug Market Will Increase by 241 Billion from 2008 to 2018 49015 1Despite Generic Erosion of Key Brands the Hospital Acquired Gram Negative Infections Drug Market Will Increase by 241 Billion from 2008 to 2018 49015 2Despite Generic Erosion of Key Brands the Hospital Acquired Gram Negative Infections Drug Market Will Increase by 241 Billion from 2008 to 2018 49015 3AirClic Mobile Business Solutions Clic for Bio Reference Laboratories Inc 49012 1AirClic Mobile Business Solutions Clic for Bio Reference Laboratories Inc 49012 2
...e that provides resistance to a fungal disease res...eld has been discovered by scientists from the US ...g more durable resistance to a devastating disease...he report, recently appointed to the John Innes Ce...previously been achieved using genes that are spec...
..., Virginia (Feb. 20, 2009) In a startling result,...Conservation Biology found that more than 80 perc...-2000 occurred in regions identified as the most b.... , Titled "Warfare in Biodiversity Hotspots," th...ntists compared major conflict zones with the Eart...
...rs at Uppsala University can now show that what is... sex. In fact, evolutionary conflicts between the...t are downright injurious to the opposite sex. Th...ournal Current Biology . , In both males and fem...ommon that one might like to think for one sex to...
Other Biology News:Gene to reduce wheat yield losses 2Study finds most wars occur in Earth's richest biological regions 2Study finds most wars occur in Earth's richest biological regions 3Mating that causes injuries 2
Bovine IgG2 ELISA Kit from Bethyl Laboratories
Dog IgE ELISA Kit from Bethyl Laboratories
PCP ELISA Kit, Single from Bio-Quant Inc.
...Protocol Development ,Antibody Titer and Optimal C...or Human Cells and Tissues ,Double Antibody Labeli...phatase, Immunogold, and Fluorescent detection ,Li...Localization in Transgenic Animals ,Hundreds of Sp...
Biology Products: